Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with Myelodysplastic Syndromes

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with Myelodysplastic Syndromes

Medicine, Hematology, Oncology, Life Sciences, Genetics,
Myelodysplastic Syndromes   Allogeneic Hematopoietic Stem-Cell Transplantation   Decision Support System   Clinical and Genomic Information   Prognostic Scoring System   Personalized Therapy  

Background Myelodysplastic Syndromes (MDS) are a group of heterogeneous diseases originating from bone marrow hematopoietic stem cells, characterized by reduced blood cell production. Although certain progress in treatment has been made in recent years, allogeneic hematopoietic stem-cell transplantation (HSCT) remains the only potentially curative ...